A Study in a Human Laboratory Model of Smoking Behavior

NCT ID: NCT02641028

Last Updated: 2025-04-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 71 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-12-31
• Study Completion Date: 2016-12-31

Brief Summary

A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior.

Detailed Description

The study will be performed in subjects who are heavy cigarette smokers currently not seeking treatment for tobacco use disorder.

The study is a crossover design study (within-subject analysis), which allows for subjects to be their own control.

Each period of the crossover consists of a 7-day out-patient treatment period followed by a single in-patient testing day on Day 8. Subjects will participate in a laboratory session following the McKee Smoking Lapse Test and be discharged from the clinic to undergo a 7 day washout period followed by the second period of the crossover design and a 7-day follow-up visit.

Conditions

Smoking

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

CERC-501

Administered orally once daily, 15mg daily, 8 days.

Group Type: EXPERIMENTAL

CERC-501

Intervention Type: DRUG

CERC-501

Placebo

Administered orally daily, 8 days.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

Interventions

CERC-501

CERC-501

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Provides written informed consent and agrees to complete required clinic visits

2. Male or female 21 to 60 years of age inclusive

3. Body mass index (BMI) 18.5 to 40 kg/m2 inclusive

4. Heavy Smokers

5. Currently not seeking smoking cessation therapy

6. In otherwise good general health without any unstable medical conditions (as determined by medical history, medication history, physical examination, 12-lead ECG, vital signs, and clinical laboratory testing)

7. Able to read, write, and speak in English

8. Females must be either:

• Post-menopausal (amenorrhea for at least 12 consecutive months), surgically sterile -or-
• Women of childbearing potential (WOCBP) must meet the criteria below:

• Uses an acceptable double-barrier method of contraception as determined by the Investigator -and-
• Is not lactating, has a negative serum beta human chorionic gonadotropin pregnancy test at screening and a negative urine pregnancy test prior to dosing on Days 1 and 8 of each treatment period.

9. Male subjects must agree to use a condom if partner is of childbearing potential

Exclusion Criteria

Subjects meeting the following criteria are not eligible for the study:

1. Any substance use disorder other than nicotine or caffeine as assessed by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) substance use disorder checklist in addition to the Mini-International Neuropsychiatric Interview (MINI) (to capture both DSM-V substance use disorder diagnoses)

2. Current neurological conditions that interfere with study conduct, assessment or treatment in any significant fashion

3. Any lifetime history of bipolar I, II; schizophrenia or any other psychotic disorders; personality disorders, impulse control disorders as assessed by the MINI

4. Current psychiatric conditions that interfere with study conduct, assessment or treatment in any significant fashion, such as major depressive disorder (MDD), eating disorders, post-traumatic stress disorder, etc., without permission of the medical monitor

5. Recent active or past history of gastric disease such as peptic ulcer disease, gastritis, upper gastrointestinal bleeding, or any gastrointestinal malignancy or precancerous condition

6. Active, comorbid disease that might limit the ability of the subject to participate in the study as determined by the Investigator (i.e., poorly controlled diabetes mellitus, congestive heart failure, etc.)

7. Clinically significant clinical laboratory test taken during screening, without permission of the Medical Monitor

8. Elevated AST or ALT ≥ 2 times the upper limit of normal (ULN)

9. Human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C positive as determined by serology testing at Screening

10. History of severe allergies or multiple adverse drug reactions

11. Known hypersensitivity to CERC-501

12. Current use of a proton pump inhibitor or histamine 2 blocker without permission of the Medical Monitor

13. Use of any investigational medication within 2 months prior to the start of this study or scheduled to receive an investigational drug other than the study drug during the course of this study

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ronald Marcus, MD

Role: STUDY_DIRECTOR

Avalo Therapeutics, Inc.

Locations

Vince and Associates

Overland Park, Kansas, United States

University of Kentucky

Lexington, Kentucky, United States

Columbia University

New York, New York, United States

Countries

United States

Other Identifiers

Clin501-201

Identifier Type: -

Identifier Source: org_study_id